Jeffrey Ginsberg

Prof. Dr. Jeffrey Ginsberg

Department of Medicine, McMaster University, Hamilton, ON, Canada

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MNMatthew Nicholson
Matthew Nicholson
NCNoel Chan
Noel Chan
VBVinai Bhagirath
Vinai Bhagirath
JGJeffrey Ginsberg
Jeffrey Ginsberg
Venous thromboembolism (VTE) is the third most common cause of vascular mortality worldwide and comprises deep-vein thrombosis (DVT) and pulmonary embolism (PE). In this review, we discuss how an understanding of VTE epidemiology and the results of thromboprophylaxis trials have shaped the current approach to VTE prevention. We will discuss modern thromboprophylaxis as it pertains to genetic risk factors, exogenous hormonal therapies, pregnancy, surgery, medical hospitalization, cancer, and what is known thus far about VTE in COVID-19 infection.

24 March 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
JGJeffrey Ginsberg
Jeffrey Ginsberg
WCWee-Shian Chan
Wee-Shian Chan
SBShannon M. Bates
Shannon M. Bates
SKScott Kaatz
Scott Kaatz
The management of pregnant women with mechanical heart valves is challenging. Recently, based on small numbers of patients and poor-quality data, correspondence from Aventis Pharmaceuticals Inc has described treatment "failures" and concerns about teratogenicity with the use of the low-molecular-weight heparin (LMWH) enoxaparin. The company issued a "Warning" that enoxaparin should not be used in patients with prosthetic heart valves and a "Precaution" about potential teratogenicity. This has created a huge problem for physicians managing pregnant women with prosthetic heart valves because the alternatives, unfractionated heparin and warfarin, are problematic. There have been case reports of failures #1including death from thrombosed valves) with unfractionated heparin, whereas the package insert for warfarin states that the drug is contraindicated during pregnancy because of potential teratogenicity. Initially, LMWHs appeared suitable for pregnant patients with prosthetic heart valves. Unfortunately, the company correspondence, presumably supported by the Food and Drug Administration (FDA), raises medicolegal concerns with use of any LMWH. We believe that pharmaceutical companies and the FDA should not endorse scientifically unsupported claims that eliminate acceptable therapeutic options. This correspondence has created considerable confusion among patients and treating physicians and is likely to lead to frivolous lawsuits and preclude the performance of properly designed trials in pregnant women. We believe a consensus conference among experts in the field to identify key unresolved issues and a commitment by the FDA and industry to perform appropriate studies are now critical.

24 July 2007 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
TIthe SOX Trial Investigators
the SOX Trial Investigators
SKSusan R Kahn
Susan R Kahn
HSHadia Shbaklo
Hadia Shbaklo
SSStan Shapiro
Stan Shapiro
PWPhilip S Wells
Philip S Wells
VTVicky Tagalakis
Vicky Tagalakis
Post thrombotic syndrome (PTS) is a burdensome and costly complication of deep venous thrombosis (DVT) that develops in 20–40% of patients within 1–2 years after symptomatic DVT. Affected patients have chronic leg pain and swelling and may develop ulcers. Venous valve disruption from the thrombus itself or thrombus-associated mediators of inflammation is considered to be a key initiating event for the development of venous hypertension that often underlies PTS. As existing treatments for PTS are extremely limited, strategies that focus on preventing the development of PTS in patients with DVT are more likely to be effective and cost-effective in reducing its burden. Elastic compression stockings (ECS) could be helpful in preventing PTS; however, data on their effectiveness are scarce and conflicting.

18 November 2014 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
NCNoel Chan
Noel Chan
DSDeborah Siegal
Deborah Siegal
MLMandy N. Lauw
Mandy N. Lauw
JGJeffrey Ginsberg
Jeffrey Ginsberg
JEJohn W. Eikelboom
John W. Eikelboom
JHJack Hirsh
Jack Hirsh

20 April 2017 in BMC Public Health
Verified
Journal Article
Open access
PDF file
DZDena Zeraatkar
Dena Zeraatkar
MOMichael Obeda
Michael Obeda
JGJeffrey Ginsberg
Jeffrey Ginsberg
JHJack Hirsh
Jack Hirsh
The media serves as an important link between medical research, as reported in scholarly sources, and the public and has the potential to act as a powerful tool to improve public health. However, concerns about the reliability of health research reports have been raised. Tools to monitor the quality of health research reporting in the media are needed to identify areas of weakness in health research reporting and to subsequently work towards the efficient use of the lay media as a public health tool through which the public’s health behaviors can be improved. We developed the Quality Index for health-related Media Reports (QIMR) as a tool to monitor the quality of health research reports in the lay media. The tool was developed according to themes generated from interviews with health journalists and researchers. Item and domain characteristics and scale reliability were assessed. The scale was correlated with a global quality assessment score and media report word count to provide evidence towards its construct validity. The items and domains of the QIMR demonstrated acceptable validity and reliability. Items from the ‘validity’ domain were negatively skewed, suggesting possible floor effect. These items were not eliminated due to acceptable content and face validity. QIMR total scores produced a strong correlation with raters’ global assessment and a moderate correlation with media report word count, providing evidence towards the construct validity of the instrument. The results of this investigation indicate that QIMR can adequately measure the quality of health research reports, with acceptable reliability and validity.

28 January 2002 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
SCSanjeev D. Chunilal
Sanjeev D. Chunilal
PBPatrick A. Brill-Edwards
Patrick A. Brill-Edwards
PSPamela B. Stevens
Pamela B. Stevens
JJJody P. Joval
Jody P. Joval
JMJoanne A. McGinnis
Joanne A. McGinnis
JGJeffrey Ginsberg
Jeffrey Ginsberg
D DIMER is a fibrin degradation product formed by the enzymatic activity of plasmin on cross-linked fibrin polymers. Plasma levels can be measured and are useful in patients who present with symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT),1,2 because negative test results (below a predefined cut point) rule out the likelihood of these diseases.